Louise Kostos

3 weeks ago | urologytimes.com | Louise Kostos |Benjamin P. Saylor

In recent video interview with Urology Times®, Dr Louise Kostos was asked for take-home points regarding a recent European Urology paper in which investigators evaluated combination therapies for the treatment of locally advanced and metastatic hormone-sensitive prostate cancer.1 “I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer, and...

1 month ago | urologytimes.com | Louise Kostos |Benjamin P. Saylor

In a recent study of combination therapies for the treatment of locally advanced and metastatic hormone-sensitive prostate cancer (mHSPC), investigators acknowledged although combination treatment regimens appear to improve survival, they can also result in long-term toxicity.1 In an interview with Urology Times®, study author Dr Louise Kostos said, “Most of the landmark ADT [androgen deprivation therapy] and ARPI [androgen receptor pathway inhibitor] trials have published quality of life...

1 month ago | urologytimes.com | Louise Kostos |Benjamin P. Saylor

A recent European Urology study examined data regarding combination therapies for the treatment of locally advanced and metastatic hormone-sensitive prostate cancer (mHSPC).1 In the paper, the investigators emphasized the importance of optimizing patient selection for combination therapies.

1 month ago | urologytimes.com | Louise Kostos |Benjamin P. Saylor

In a recent study in European Urology, investigators sought to review data regarding combination therapies for the treatment of locally advanced and metastatic hormone-sensitive prostate cancer.1 In their paper, the authors touched on the integration of prostate-specific membrane antigen (PSMA) PET imaging leading to earlier detection of metastatic disease.

1 month ago | urologytimes.com | Louise Kostos |Benjamin P. Saylor

In this video, Dr Louise Kostos discusses patient subgroups that see the most benefit from triplet regimens incorporating docetaxel in metastatic hormone-sensitive prostate cancer. She is an author of the recent European Urology paper “Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.” Kostos is a medical oncologist and PhD candidate at Peter MacCallum Cancer Centre in Victoria, Australia.